Core Insights - The ENSURE II study results have been published in the peer-reviewed journal Nature Medicine, evaluating the efficacy and safety of the siRNA drug elebsiran in combination with PEG-IFNα for chronic hepatitis B treatment [1] - The study also explores the potential role of the therapeutic vaccine BRII-179 in identifying immune responders and increasing HBsAg clearance rates [1] Group 1 - The ENSURE study was conducted in two parts, with the first part involving chronic HBV patients who had not previously received BRII-179, randomly assigned to either 48 weeks of PEG-IFNα monotherapy or combination therapy with elebsiran [2] - The second part involved participants who had previously received elebsiran and BRII-179, categorized based on their anti-HBs peak levels, and subsequently treated with elebsiran and PEG-IFNα [2] Group 2 - Professor Jia Jidong, the lead investigator of the ENSURE study, emphasized the study's aim to provide scientific evidence for curative therapies for chronic hepatitis B and highlighted encouraging trends in the 24-week follow-up data supporting the clinical benefits of elebsiran [3] - The study suggests a potential new role for BRII-179 in activating the immune response in chronic HBV patients, aiming for higher functional cure rates [3]
腾盛博药-B：在《自然 医学》发表ENSURE II期研究结果